CEO David W. Miller explains what we mean when we say we help our life science clients to ‘Innovate differently’ and transform the way they engage with research partners.
Earlier in 2024, our webinar ‘Fit-for-purpose matchmaking: a data selection and RWE approach for both regulatory and HTA audiences’ took place with Allie Sosinsky, Director, Pharmacoepidemiology and Safety, and Carole Longson MBE, Professor and Independent Senior Advisor. Explore our RWE expertise.
In March 2024, Genesis Research Group’s Katrin Nather and Tijana Ignjatovic presented at World EPA Congress on the subject of ‘Shining the light on vaccine market access’. Discover our RPR-powered access and pricing capabilities.
ITN Business invited Genesis Research Group to contribute to a news style programme ‘Advancing Healthcare’ featuring key opinion leaders in the healthcare industry talking about how best to confront its challenges.
An interview with Executive Director Tijana Ignjatovic regarding Envision, a platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive EMA or FDA guidance. Download our Envision brochure.
Our unique Flexible Integrated Team (FIT) engagement model represents a paradigm shift in how companies engage with a pharmaceutical, biotech and medical device research partners. Find out more.
Priti Jhingran and Tijana Ignjatovic present a HealthEconomics.com webinar describing how actionable payer insights facilitate an informed approach to evidence generation that is meaningful to payer, HTA, and medical decision-makers. Read more about RPR.
In May 2023, Jen Wogen and Craig S. Parzynski presented at ISPOR 23 on ‘Developing Fit-for-Purpose External Control Arms to Optimize Submissions to Regulatory and Health Technology Assessment Agencies.’ Discover our ECA and RWE capabilities.
At the World EPA Congress in March 2023, VP, Evidence Strategy Priti Jhingran delivered a presentation on ‘Stakeholder Validation of Evidence Generation Plans (EGPs) to Achieve Optimal Access’. Read more about stakeholder insights.
RPR provides robust, transparent, survey-based stakeholder engagement in a fraction of the time and cost of traditional methods, plus the ability to ask participants clarificatory and follow-up questions. Read about RPR.
Efficiency Is The New Normal by David W. Miller, Ph.D, CEO,
Genesis Research Group
The Role of External Control Arms in Drug Development and Considerations for Success by Alexandra Z. Sosinsky, Craig S. Parzynski, and Deborah Casso
Headquarters:
HOBOKEN
111 River Street, Suite 1120
Hoboken, New Jersey 07030, US
